Verve Therapeutics Announces Updates on its PCSK9 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Verve Therapeutics (VERV) PT Lowered to $30 at BMO Capital
April 3, 2024 7:43 AM EDTBMO Capital analyst Kostas Biliouris lowered the price target on Verve Therapeutics (NASDAQ: VERV) to $30.00 (from $56.00) while maintaining a Outperform rating.
The analyst commented, "Management will prioritize VERVE-102 due to a Gr3 AE under 0.45mpk VERVE-101. We believe the durable (>270d) and... More
Verve Therapeutics (VERV) PT Lowered to $40 at Stifel
April 2, 2024 4:52 PM EDTStifel analyst Dae Gon Ha lowered the price target on Verve Therapeutics (NASDAQ: VERV) to $40.00 (from $56.00) while maintaining a Buy rating.
The analyst comments "Shares are sharply lower following an earlier VERVE-101 update (LINK) likely amplified by the small dataset backing the... More
